WO2009138487A1 - Pharmaceutical compositions for the treatment of warts - Google Patents

Pharmaceutical compositions for the treatment of warts Download PDF

Info

Publication number
WO2009138487A1
WO2009138487A1 PCT/EP2009/055904 EP2009055904W WO2009138487A1 WO 2009138487 A1 WO2009138487 A1 WO 2009138487A1 EP 2009055904 W EP2009055904 W EP 2009055904W WO 2009138487 A1 WO2009138487 A1 WO 2009138487A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
oil
warts
treatment
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/055904
Other languages
French (fr)
Inventor
Mario Dominik Nicolaas Oldani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATP MARKETING AND PROMOTION AG
Original Assignee
ATP MARKETING AND PROMOTION AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2011508935A priority Critical patent/JP5442003B2/en
Priority to SI200930251T priority patent/SI2285367T1/en
Priority to AT09745819T priority patent/ATE546137T1/en
Priority to DK09745819.4T priority patent/DK2285367T3/en
Priority to HRP20120326AT priority patent/HRP20120326T1/en
Priority to ES09745819T priority patent/ES2382959T3/en
Priority to CN2009801178085A priority patent/CN102026635A/en
Priority to EA201071308A priority patent/EA018216B1/en
Priority to CA2723834A priority patent/CA2723834A1/en
Application filed by ATP MARKETING AND PROMOTION AG filed Critical ATP MARKETING AND PROMOTION AG
Priority to US12/992,166 priority patent/US20110117222A1/en
Priority to PL09745819T priority patent/PL2285367T3/en
Priority to EP09745819A priority patent/EP2285367B1/en
Publication of WO2009138487A1 publication Critical patent/WO2009138487A1/en
Priority to ZA2010/08022A priority patent/ZA201008022B/en
Anticipated expiration legal-status Critical
Priority to US14/029,031 priority patent/US20140057006A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Definitions

  • the present invention relates to pharmaceutical compositions for the treatment, and especially the topical treatment, of warts and the use thereof for the treatment of warts .
  • a wart (Verrucca) is a hard, or horny, callous deformity of the upper skin generally in the form of a cauliflower-like nodule.
  • warts generally comprise a core of connective tissue, and comprised therein blood vessels, coated with one or more layers of epithelial tissue. Warts can occur alone or in groups .
  • Warts are generally caused by human papilloma viruses. Papilloma virus infected skin cells grow faster than non-infected skin cells. This growth difference, in comparison with the surrounding skin cells, results in a wart. Because of their virulent nature, warts are contagious . Although in most cases warts do not cause other adverse medical conditions, and even spontaneously disappear after a certain time period, individuals receiving organ transplants, or other individuals with a compromised immune system, often develop warts on their hands and lower arms which warts sometimes appear to develop into squamous cell carcinomas .
  • Cryosurgery which involves freezing the wart (generally with liquid nitrogen) , creating a blister between the wart and epidermal layer, after which the wart and surrounding dead skin falls off.
  • An average of 3 to 4 treatment is required for warts of thin skin. Warts on calloused skin like plantar warts might take dozens or more treatments.
  • Pulse dye lasers work by selective absorption by blood cells (specifically haemoglobin) .
  • CO 2 lasers work by selective absorption by water molecules. Pulse dye lasers are less destructive and more likely to heal without scarring.
  • CO 2 laser works by vaporizing and destroying tissue and skin. Both laser treatments can be painful, expensive, and can cause scarring. CO 2 lasers will require local anaesthetic, while pulse dye lasers might need conscious sedation.
  • the therapy comprises 1 to 4 treatments.
  • Infrared coagulator an intense source of infrared light in a small beam like a laser. This works essentially on the same principle as laser treatment. Like the laser, it can cause blistering, pain and scarring.
  • Imiquimod a topical cream that helps the body's immune system combat the wart virus by encouraging interferon production.
  • Cantharidin a chemical found naturally in many members of the beetle family Meloidae which causes dermal blistering. Either used by itself or compounded with podophyllin.
  • Bleomycin one or two injections are used. Bleomycin can cause necrosis of digits and Raynaud syndrome .
  • DNCB Dinitrochlorobenzene
  • DNCB must be used much more cautiously than salicylic acid; the chemical is a known mutagen and, therefore, capable of causing genetic mutations.
  • This drug induces an allergic immune response resulting in inflammation that wards off the wart-causing virus .
  • Fluorouracil which inhibits DNA synthesis, is being used as an experimental treatment. It is applied directly to the wart (especially plantar warts) and covered with, for example, tape. This treatment is combined with the use of a pumice stone, but tends to work very slowly.
  • compositions for the treatment of warts comprising: a) 0.1 to 10 weight% dimethicone; b) 5 to 25 weight% of one or more vegetable oils,- c) one or more pharmaceutically acceptable excipients and/or carriers; d) 2 to 6 weight% urea,- and e) water up to 100 weight% .
  • dimethicone polydimethylsolixane, PDMS
  • PDMS dimethylsolixane
  • compositions according to the present invention comprise urea.
  • Urea because of its water retention (wetting) characteristics is one of the most important water retention compounds of the skin.
  • compositions also beneficially comprise one or more vegetable oils and one or more pharmaceutically acceptable excipients and/or carriers.
  • the one or more vegetable oils are chosen from the group consisting of almond oil, tea tree oil, lavender oil, geranium oil, lemon oil, thuja oil, and cinnamon oil.
  • Almond oil for example, beneficially regulates the moisture content of the skin and reduces skin irritations .
  • Lavender oil for example, beneficially provides disinfecting, bactericide, pain killing, curing and purifying characteristics.
  • Geranium oil for example, beneficially provides infection inhibiting, fungus inhibiting and wound healing characteristics .
  • Tea tree oil for example, beneficially provides bacterial, viral and fungal inhibiting growth characteristics. Further, tea tree oil is pain and scar reducing, and improves healing. Furthermore, tea tree oil readily mixes with natural skin oils allowing a quick effect on the source of infection.
  • Cinnamon oil for example, aids in combating bacteria, viruses and fungi, is inflammation inhibiting and improves the blood flow.
  • Thuja oil for example, is a bactericide and fungicide.
  • Lemon oil for example, is disinfecting.
  • the present pharmaceutical composition further comprises 0.5 to 2 weight% red pepper powder.
  • Red pepper also designated as Chilean or Spanish pepper or hot pepper, is rich in vitamin C, reduces pain, stimulates nerves, and is disinfecting.
  • the present one or more excipients and/or carriers are chosen from the group consisting of ammonium acryloyldimethyl taurate/ VP copolymer, sodium benzoate, potassium sorbate and citric acid.
  • the pharmaceutical compositions comprise: a) 0.5 to 3 weight% dimethicone; b) vegetable oils comprising.-
  • the pharmaceutical compositions comprise: a) 1 weight% dimethicone; b) vegetable oils comprising: 1) 2 weight% almond oil;
  • compositions according to the present invention are, in a preferred embodiment, formulated for topical administration, preferably in the form of an ointment, creme or tincture.
  • the present pharmaceutical compositions are especially effective for the treatment of warts. Accordingly, the present invention also relates to dimethicone for the topical treatment of warts and the use of dimethicone for the preparation of a medicament for the topical treatment of warts.
  • a beneficial effect of the present pharmaceutical compositions, and the use thereof, is further provided by the observation that the wart surrounding skin substantially remains unaffected by the present compositions.
  • the present pharmaceutical compositions are suitably, for example and preferably, topically applied, 1 to 5 times a day, preferably 1 to 2 times a day, on the wart. After application, the present pharmaceutical composition is massaged in and allowed to be absorbed. The indicated treatment is repeated until the wart has at least visibly disappeared.
  • the indicated treatment regime using the present compositions has been used by a number of individuals repeatedly suffering from warts and a significant subset of these individuals reported the disappearance of the warts within a time period of 1 week to several months without pain, scarring or any other side effects.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical compositions for the treatment, and especially topical treatment, of warts and the use thereof for the treatment of warts. Specifically, the present invention relates to pharmaceutical compositions for the treatment of warts, comprising: a) 0.1 to 10 weight % dimethicone; b) 5 to 25 weight % of one or more vegetable oils; c) one or more pharmaceutically acceptable excipients and/or carriers; d) 2 to 6 weight % urea; and e) water up to 100 weight %.

Description

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF WARTS
Description
The present invention relates to pharmaceutical compositions for the treatment, and especially the topical treatment, of warts and the use thereof for the treatment of warts .
A wart (Verrucca) , is a hard, or horny, callous deformity of the upper skin generally in the form of a cauliflower-like nodule. At least four different types of warts are known.- the common wart (Verruca vulgaris) , the plantar wart {Verucca plantaris) , the flat wart {Verucca plana) and the filiform wart (Verucca filiformis) . Warts generally comprise a core of connective tissue, and comprised therein blood vessels, coated with one or more layers of epithelial tissue. Warts can occur alone or in groups .
Warts are generally caused by human papilloma viruses. Papilloma virus infected skin cells grow faster than non-infected skin cells. This growth difference, in comparison with the surrounding skin cells, results in a wart. Because of their virulent nature, warts are contagious . Although in most cases warts do not cause other adverse medical conditions, and even spontaneously disappear after a certain time period, individuals receiving organ transplants, or other individuals with a compromised immune system, often develop warts on their hands and lower arms which warts sometimes appear to develop into squamous cell carcinomas .
For the treatment of warts, several methods are known from the prior art . 1) Application of podophyllum resin paint
[podophyllum resin I. P. '66 (20% w/v) , benzoin I. P. (10% w/v), aloes I. P. (2% w/v), isopropyl alcohol I. P. to make (100% v/v) ] ; 2) Keratolysis, the removal of dead surface skin cells usually using salicylic acid, blistering agents, immune system modifiers ("immunomodulators") , or formaldehyde, often with mechanical paring of the wart with a pumice stone, blade etc.;
3) Cryosurgery, which involves freezing the wart (generally with liquid nitrogen) , creating a blister between the wart and epidermal layer, after which the wart and surrounding dead skin falls off. An average of 3 to 4 treatment is required for warts of thin skin. Warts on calloused skin like plantar warts might take dozens or more treatments.
4) Surgical curettage of the wart; 5) Laser treatment, often with a pulse dye laser or carbon dioxide (CO2) laser. Pulse dye lasers work by selective absorption by blood cells (specifically haemoglobin) . CO2 lasers work by selective absorption by water molecules. Pulse dye lasers are less destructive and more likely to heal without scarring. CO2 laser works by vaporizing and destroying tissue and skin. Both laser treatments can be painful, expensive, and can cause scarring. CO2 lasers will require local anaesthetic, while pulse dye lasers might need conscious sedation. The therapy comprises 1 to 4 treatments. 6) Infrared coagulator, an intense source of infrared light in a small beam like a laser. This works essentially on the same principle as laser treatment. Like the laser, it can cause blistering, pain and scarring.
7) Imiquimod, a topical cream that helps the body's immune system combat the wart virus by encouraging interferon production.
8) Injection of Candida, mumps, or Trichophyton antigens at the site of the wart, which stimulates the body's immune system.
9) Cantharidin, a chemical found naturally in many members of the beetle family Meloidae which causes dermal blistering. Either used by itself or compounded with podophyllin.
10) Bleomycin, one or two injections are used. Bleomycin can cause necrosis of digits and Raynaud syndrome .
11) Dinitrochlorobenzene (DNCB) , like salicylic acid, this is applied directly onto the wart.
Studies showed this method was effective with a cure rate of 80% compared to 38% for a placebo. But DNCB must be used much more cautiously than salicylic acid; the chemical is a known mutagen and, therefore, capable of causing genetic mutations. This drug induces an allergic immune response resulting in inflammation that wards off the wart-causing virus . 12) Fluorouracil, which inhibits DNA synthesis, is being used as an experimental treatment. It is applied directly to the wart (especially plantar warts) and covered with, for example, tape. This treatment is combined with the use of a pumice stone, but tends to work very slowly.
However, none of the above mentioned methods provide an effective, or satisfying treatment of warts.
Accordingly, it an object of the present invention to provide novel pharmaceutical compositions for the treatment, and especially the topical treatment, of warts.
This object, amongst other objects, is met by the pharmaceutical compositions for the treatment of warts as defined in the appended claim 1.
Specifically, this object, amongst other objects, is met by pharmaceutical compositions for the treatment of warts comprising: a) 0.1 to 10 weight% dimethicone; b) 5 to 25 weight% of one or more vegetable oils,- c) one or more pharmaceutically acceptable excipients and/or carriers; d) 2 to 6 weight% urea,- and e) water up to 100 weight% .
As used herein, the term weight% relates to the weight of the indicated ingredient divided by the weight of the total pharmaceutical composition and multiplied by 100%. Dimethicone (polydimethylsolixane, PDMS) is a flexible silicon polymer generally used in hand lotions and cosmetic products. The present inventor surprisingly discovered that besides this known use of dimethicone, dimethicone also has a beneficial effect on the treatment of warts.
The pharmaceutical compositions according to the present invention comprise urea. Urea, because of its water retention (wetting) characteristics is one of the most important water retention compounds of the skin.
Besides dimethicone and urea, the present pharmaceutical compositions also beneficially comprise one or more vegetable oils and one or more pharmaceutically acceptable excipients and/or carriers.
In a preferred embodiment of the present invention, the one or more vegetable oils are chosen from the group consisting of almond oil, tea tree oil, lavender oil, geranium oil, lemon oil, thuja oil, and cinnamon oil.
Almond oil, for example, beneficially regulates the moisture content of the skin and reduces skin irritations .
Lavender oil, for example, beneficially provides disinfecting, bactericide, pain killing, curing and purifying characteristics.
Geranium oil, for example, beneficially provides infection inhibiting, fungus inhibiting and wound healing characteristics . Tea tree oil, for example, beneficially provides bacterial, viral and fungal inhibiting growth characteristics. Further, tea tree oil is pain and scar reducing, and improves healing. Furthermore, tea tree oil readily mixes with natural skin oils allowing a quick effect on the source of infection.
Cinnamon oil, for example, aids in combating bacteria, viruses and fungi, is inflammation inhibiting and improves the blood flow.
Thuja oil, for example, is a bactericide and fungicide.
Lemon oil, for example, is disinfecting.
According to a preferred embodiment, the present pharmaceutical composition further comprises 0.5 to 2 weight% red pepper powder. Red pepper, also designated as Chilean or Spanish pepper or hot pepper, is rich in vitamin C, reduces pain, stimulates nerves, and is disinfecting. Preferably, the present one or more excipients and/or carriers are chosen from the group consisting of ammonium acryloyldimethyl taurate/ VP copolymer, sodium benzoate, potassium sorbate and citric acid.
According to an especially preferred embodiment of the present invention, the pharmaceutical compositions comprise: a) 0.5 to 3 weight% dimethicone; b) vegetable oils comprising.-
1) 1 to 3 weight% almond oil;
2) 1 to 3 weight% tea tree oil; 3) 1 to 2 weight% lavender oil;
4) 1 to 2 weight% geranium oil;
5) 0.5 to 2 weight% lemon oil,-
6) 0.5 to 2 weight% thuja oil;
7) 0.5 to 2 weight% cinnamon oil. c) pharmaceutically acceptable excipients and/or carriers comprising-.
1) 0.5 to 3 weight% ammonium acryloyldimethyl taurate/ VP copolymer;
2) 0.1 to 0.5 weight% sodium benzoate; 3) 0.05 to 0.25 weight% potassium sorbate;
4) 0.05 to 0.25 weight% citric acid; d) 2 to 6 weight% urea,- e) 0.5 to 3 weight% red pepper powder; f) water up to 100 weight% . According to a most preferred embodiment of the present invention, the pharmaceutical compositions comprise: a) 1 weight% dimethicone; b) vegetable oils comprising: 1) 2 weight% almond oil;
2) 2 weight% tea tree oil;
3) 1.5 weight% lavender oil;
4) 1.5 weight% geranium oil; 5) 1 weight% lemon oil;
6) 1 weight% thuja oil;
7) 1 weight% cinnamon oil. c) pharmaceutically acceptable excipients and/or carriers comprising: 1) 1.65 weight% ammonium acryloyldimethyl taurate/ VP copolymer,-
2) 0.3 weight% sodium benzoate,-
3) 0.16 weight% potassium sorbate,-
4) 0.15 weight% citric acid; d) 4 weight% urea; e) 1 weight% red pepper powder,- f) water up to 100 weight% .
The pharmaceutical compositions according to the present invention are, in a preferred embodiment, formulated for topical administration, preferably in the form of an ointment, creme or tincture.
The present pharmaceutical compositions are especially effective for the treatment of warts. Accordingly, the present invention also relates to dimethicone for the topical treatment of warts and the use of dimethicone for the preparation of a medicament for the topical treatment of warts.
A beneficial effect of the present pharmaceutical compositions, and the use thereof, is further provided by the observation that the wart surrounding skin substantially remains unaffected by the present compositions.
The present pharmaceutical compositions are suitably, for example and preferably, topically applied, 1 to 5 times a day, preferably 1 to 2 times a day, on the wart. After application, the present pharmaceutical composition is massaged in and allowed to be absorbed. The indicated treatment is repeated until the wart has at least visibly disappeared.
The indicated treatment regime using the present compositions has been used by a number of individuals repeatedly suffering from warts and a significant subset of these individuals reported the disappearance of the warts within a time period of 1 week to several months without pain, scarring or any other side effects.

Claims

1. Pharmaceutical composition for the treatment of warts, comprising: a) 0.1 to 10 weight% dimethicone; b) 5 to 25 weight% of one or more vegetable oils,- c) one or more pharmaceutically acceptable excipients and/or carriers,- d) 2 to 6 weight% urea,- and e) water up to 100 weight%.
2. Pharmaceutical composition according to claim 1, wherein said one or more vegetable oils are chosen from the group consisting of almond oil, tea tree oil, lavender oil, geranium oil, lemon oil, thuja oil, and cinnamon oil.
3. Pharmaceutical composition according to claim 1 or claim 2, further comprising: f) 0.5 to 2 weight% red pepper powder.
4. Pharmaceutical composition according to any of the claims 1 to 3 , wherein said one or more pharmaceutically acceptable excipients and/or carriers are chosen from the group consisting of ammonium acryloyldimethyl taurate/ VP copolymer, sodium benzoate, potassium sorbate and citric acid.
5. Pharmaceutical composition according to any of the claims 1 to 4 , comprising: a) 0.5 to 3 weight% dimethicone; b) vegetable oils comprising.-
1) 1 to 3 weight% almond oil; 2) 1 to 3 weight% tea tree oil;
3) 1 to 2 weight% lavender oil;
4) 1 to 2 weight% geranium oil;
5) 0.5 to 2 weight% lemon oil; 6) 0.5 to 2 weight% thuja oil;
7) 0.5 to 2 weight% cinnamon oil. c) pharmaceutically acceptable excipients and/or carriers comprising-.
1) 0.5 to 3 weight% ammonium acryloyldimethyl taurate/ VP copolymer;
2) 0.1 to 0.5 weight% sodium benzoate;
3) 0.05 to 0.25 weight% potassium sorbate,-
4) 0.05 to 0.25 weight% citric acid,- d) 2 to 6 weight% urea,- e) 0.5 to 3 weight% red pepper powder,- f) water up to 100 weight%.
6. Pharmaceutical composition according to any one of the claims 1 to 5, comprising: a) 1 weight% dimethicone,- b) vegetable oils comprising-.
1) 2 weight% almond oil;
2) 2 weight% tea tree oil;
3) 1.5 weight% lavender oil; 4) 1.5 weight% geranium oil;
5) 1 weight% lemon oil,-
6) 1 weight% thuja oil;
7) 1 weight% cinnamon oil. c) pharmaceutically acceptable excipients and/or carriers comprising:
1) 1.65 weight% ammonium acryloyldimethyl taurate/ VP copolymer,-
2) 0.3 weight% sodium benzoate; 3) 0.16 weight% potassium sorbate,-
4) 0.15 weight% citric acid; d) 4 weight% urea; e) 1 weight% red pepper powder; f) water up to 100 weight%.
7. Pharmaceutical composition according to any of the claims 1 to 6 in a dosage form for topical administration.
8. Pharmaceutical composition according to claim 7, wherein the topical dosage form is an ointment, creme or tincture.
9. Dimethicone for the topical treatment of warts.
10. Use of dimethicone for the preparation of a medicament for the topical treatment of warts.
PCT/EP2009/055904 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts Ceased WO2009138487A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA2723834A CA2723834A1 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts
AT09745819T ATE546137T1 (en) 2008-05-15 2009-05-15 PHARMACEUTICAL COMPOSITIONS FOR TREATING WARTS
DK09745819.4T DK2285367T3 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts
HRP20120326AT HRP20120326T1 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts
ES09745819T ES2382959T3 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts
CN2009801178085A CN102026635A (en) 2008-05-15 2009-05-15 Pharmaceutical composition for treating warts
EA201071308A EA018216B1 (en) 2008-05-15 2009-05-15 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT FOR WARFARE
JP2011508935A JP5442003B2 (en) 2008-05-15 2009-05-15 Pharmaceutical composition for the treatment of warts
US12/992,166 US20110117222A1 (en) 2008-05-15 2009-05-15 Pharmaceutical Compositions for the Treatment of Warts
SI200930251T SI2285367T1 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts
PL09745819T PL2285367T3 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts
EP09745819A EP2285367B1 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts
ZA2010/08022A ZA201008022B (en) 2008-05-15 2010-11-09 Pharmaceutical compositions for the treatment of warts
US14/029,031 US20140057006A1 (en) 2008-05-15 2013-09-17 Pharmaceutical Compositions for the Treatment of Warts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NLNL1035426 2008-05-15
NL1035426A NL1035426C2 (en) 2008-05-15 2008-05-15 Pharmaceutical compositions for the treatment of warts.

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/992,166 A-371-Of-International US20110117222A1 (en) 2008-05-15 2009-05-15 Pharmaceutical Compositions for the Treatment of Warts
US14/029,031 Continuation US20140057006A1 (en) 2008-05-15 2013-09-17 Pharmaceutical Compositions for the Treatment of Warts

Publications (1)

Publication Number Publication Date
WO2009138487A1 true WO2009138487A1 (en) 2009-11-19

Family

ID=40085549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/055904 Ceased WO2009138487A1 (en) 2008-05-15 2009-05-15 Pharmaceutical compositions for the treatment of warts

Country Status (16)

Country Link
US (2) US20110117222A1 (en)
EP (1) EP2285367B1 (en)
JP (1) JP5442003B2 (en)
CN (1) CN102026635A (en)
AT (1) ATE546137T1 (en)
CA (1) CA2723834A1 (en)
CY (1) CY1114028T1 (en)
DK (1) DK2285367T3 (en)
EA (1) EA018216B1 (en)
ES (1) ES2382959T3 (en)
HR (1) HRP20120326T1 (en)
NL (1) NL1035426C2 (en)
PL (1) PL2285367T3 (en)
SI (1) SI2285367T1 (en)
WO (1) WO2009138487A1 (en)
ZA (1) ZA201008022B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082172A1 (en) * 2013-12-03 2015-06-11 Zzip Ag Polydimethylsiloxane for the treatment of viral infections
CH710459A1 (en) * 2014-12-10 2016-06-15 Blum Charles Mix repellent against ticks.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197291A1 (en) * 2001-05-30 2002-12-26 Horst Ulbricht Composition for removing abnormal keratinous material
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3136593A (en) * 1991-11-22 1993-06-15 Richardson-Vicks Inc. Combined personal cleansing and moisturizing compositions
US5871760A (en) * 1994-11-28 1999-02-16 The Procter & Gamble Company Skin care compositions
TW504387B (en) * 1995-09-06 2002-10-01 Kao Corp Emulsified, water-in-oil type composition and skin cosmetic preparation
EP1159954A3 (en) * 2000-05-31 2003-01-02 Shiseido Company, Ltd. Solid water-in-oil type emulsion cosmetic composition
WO2003011303A1 (en) * 2001-07-27 2003-02-13 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
JP2006335680A (en) * 2005-06-02 2006-12-14 Gero Kosha:Kk Topical skin preparation
US20080182903A1 (en) * 2006-12-11 2008-07-31 Kaleem Ahmad Formulation of a composition for treating various conditions by using lotion/cream including L-Arginine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197291A1 (en) * 2001-05-30 2002-12-26 Horst Ulbricht Composition for removing abnormal keratinous material
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIGASHI N ET AL: "Recalcitrant plantar warts treated with topical 10% urea ointment", SKIN RESEARCH, vol. 42, no. 5, 2000, pages 498 - 502, XP008099574 *
HIGASHI NOBUHIKO ET AL: "Treatment of Verruca Plana with Urea Ointment (Urepal)", SKIN RESEARCH, vol. 36, no. 1, 1994, pages 55 - 59, XP008099573 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015082172A1 (en) * 2013-12-03 2015-06-11 Zzip Ag Polydimethylsiloxane for the treatment of viral infections
CH710459A1 (en) * 2014-12-10 2016-06-15 Blum Charles Mix repellent against ticks.
EP3031327A1 (en) 2014-12-10 2016-06-15 Charles Blum Repellent mixture against ticks

Also Published As

Publication number Publication date
HRP20120326T1 (en) 2012-05-31
CN102026635A (en) 2011-04-20
CA2723834A1 (en) 2009-11-19
EA201071308A1 (en) 2011-04-29
ZA201008022B (en) 2012-02-29
JP2011520843A (en) 2011-07-21
US20140057006A1 (en) 2014-02-27
PL2285367T3 (en) 2012-07-31
DK2285367T3 (en) 2012-06-18
EP2285367A1 (en) 2011-02-23
JP5442003B2 (en) 2014-03-12
NL1035426C2 (en) 2009-11-17
US20110117222A1 (en) 2011-05-19
SI2285367T1 (en) 2012-06-29
ATE546137T1 (en) 2012-03-15
CY1114028T1 (en) 2016-07-27
ES2382959T3 (en) 2012-06-14
EA018216B1 (en) 2013-06-28
EP2285367B1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
US8333981B2 (en) Antifungal treatment of nails
US9107920B2 (en) Extract of Trigonella foenum-graecum
EP0954278B1 (en) Pharmaceutical compositions containing kukui nut oil
EP0870507A1 (en) Synergistic herbal extracts
WO1993011780A1 (en) Skin therapeutic mixture containing cold-processed aloe vera extract, with yellow sap and aloin removed
EP2896396A1 (en) Herbal formulation for topical wound treatment
EP2501366B1 (en) Anti-viral composition
FR2504551A1 (en) AROMATIC COMPOSITIONS HAVING BIOLOGICAL PROPERTIES AND MEDICINES CONTAINING THEM
US20160101139A1 (en) Topical treatment for use as a sleep aid
EP2285367B1 (en) Pharmaceutical compositions for the treatment of warts
JP2024516248A (en) Wound Care Composition
US10071052B2 (en) Method for the prevention and treatment of acne
JPH05320063A (en) Active oxygen-inhibiting agent
CN106822321B (en) Application of Curcuma water of traumatology in preparing medicine for treating keratosis pilaris
KR100682979B1 (en) Composition for prophylactic treatment against antimicrobial infection and anti-inflammatory action and athlete&#39;s foot therapeutic agent obtained using the composition
US5576005A (en) Effectiveness of wart removal by compositions including propolis
ES2269627T3 (en) ASSOCIATION OF ARNICA, RUSCO AND MENTOL.
CN106619751A (en) External medicine for treating tinea unguium
US20040126445A1 (en) Laurel based healing composition
WO2020201847A1 (en) Herbal composition for the treatment of burns
Bhattacharjee et al. Podophyllin
WO2016140629A1 (en) A topical composition comprising calendula, hypericum and lidocaine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980117808.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09745819

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2723834

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2011508935

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009745819

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4621/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 201071308

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12992166

Country of ref document: US